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Abstract
Background: Osteopontin represents a multifunctional molecule playing a pivotal role in chronic inflammatory and
autoimmune diseases. Its expression is increased in inflammatory bowel disease (IBD). The aim of our study was to analyze
the association of osteopontin (OPN/SPP1) gene variants in a large cohort of IBD patients.
Methodology/Principal Findings: Genomic DNA from 2819 Caucasian individuals (n=841 patients with Crohn’s disease
(CD), n=473 patients with ulcerative colitis (UC), and n=1505 healthy unrelated controls) was analyzed for nine OPN SNPs
(rs2728127, rs2853744, rs11730582, rs11739060, rs28357094, rs4754=p.Asp80Asp, rs1126616=p.Ala236Ala, rs1126772 and
rs9138). Considering the important role of osteopontin in Th17-mediated diseases, we performed analysis for epistasis with
IBD-associated IL23R variants and analyzed serum levels of the Th17 cytokine IL-22. For four OPN SNPs (rs4754, rs1126616,
rs1126772 and rs9138), we observed significantly different distributions between male and female CD patients. rs4754 was
protective in male CD patients (p=0.0004, OR=0.69). None of the other investigated OPN SNPs was associated with CD or
UC susceptibility. However, several OPN haplotypes showed significant associations with CD susceptibility. The strongest
association was found for a haplotype consisting of the 8 OPN SNPs rs2728127-rs2853744-rs11730582-rs11439060-
rs28357094-rs112661-rs1126772-rs9138 (omnibus p-value=2.07610
28). Overall, the mean IL-22 secretion in the combined
group of OPN minor allele carriers with CD was significantly lower than that of CD patients with OPN wildtype alleles
(p=3.66610
25). There was evidence for weak epistasis between the OPN SNP rs28357094 with the IL23R SNP rs10489629
(p=4.18610
22) and between OPN SNP rs1126616 and IL23R SNP rs2201841 (p=4.18610
22) but none of these associations
remained significant after Bonferroni correction.
Conclusions/Significance: Our study identified OPN haplotypes as modifiers of CD susceptibility, while the combined
effects of certain OPN variants may modulate IL-22 secretion.
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Introduction
The pathogenesis of inflammatory bowel diseases (IBD) such as
Crohn’s disease (CD) and ulcerative colitis (UC) is only partially
understood. Currently, these diseases are assumed to be triggered
by an exaggerated immune response to intestinal bacteria in a
genetically susceptible host. In addition to the nucleotide-binding
oligomerization domain 2/caspase recruitment domain-containing
protein 15 (NOD2/CARD15) [1,2], various novel susceptibility loci
such as the interleukin-23 receptor (IL23R) [3,4], the ATG16L1
(autophagy-related 16-like 1) gene [5,6] and variants in the 5p13.1
region [7] have been identified as susceptibility variants in CD
patients. Based on new insights in the genetic background of CD,
there is raising evidence for a key role of innate immunity and CD-
related inflammatory pathways such as IL-23/IL-17 mediated T
cell responses [8]. Recently, osteopontin (OPN, also known as Eta-
1), an extracellular matrix glycosylated phosphoprotein produced
by immune cells, epithelial cells and osteoblasts has been identified
as an important molecule involved in tissue repair, inflammation
and autoimmunity as well as tumour growth [9,10,11,12]. So far,
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osteopontin (sOPN) seems to be involved in the production of
pathogenetic Th1 and Th17 cells, while an intracellular form of
osteopontin (iOPN) is a key regulator for Toll like receptor-9
(TLR9) and/or TLR7-dependent interferon-a (IFN-a) expression
by plasmacytoid dendritic cells (DCs) and Th17 development [13].
There is evidence for a key role of osteopontin in Th1- and Th17-
mediated diseases [10,14,15] such as rheumatoid arthritis
[16,17,18], psoriasis [19] and multiple sclerosis [20,21,22,23]. In
addition, osteopontin has also shown to be involved in granuloma
formation [10], cell migration [24,25,26], and IL-12 production
[27,28,29].
Osteopontin is expressed in the terminal ileum of CD patients
[30] and seems to be closely involved in the Th1 immune response
associated with CD [31,32,33,34]. Moreover, it has also been
reported to play an important role in the pathogenesis of UC
[35,36,37,38]. Analyzing the exact role of osteopontin in a murine
model of acute colitis, a recent study demonstrated that Opn
2/2
mice showed increased serum levels of TNF-a but also reduced
mRNA expression of IL-1b and matrix metalloproteinases as well
as decreased blood levels of IL-22 [39]. In contrast, in a chronic
DSS model, Opn
2/2 mice were protected from mucosal
inflammation showing lower serum IL-12 levels compared to
wildtype mice and neutralization of OPN in wildtype mice
abrogated colitis [39]. These findings implicate a dual function
of osteopontin in intestinal inflammation characterized by
activation of innate immunity and Th17 cytokines such as IL-22
initiating mucosal repair in acute inflammation; while under
conditions of chronic intestinal inflammation it may promote the
Th1 response and thereby enhancing inflammation [39]. Further
investigations by daSilva et al. in a DSS model demonstrated that
osteopontin administration reduced the disease activity index,
improved red blood cell counts, and reduced gut neutrophil
activity compared with the DSS-treated wildtype mice [37].
Interestingly, the study by Heilmann et al. demonstrated a
significant correlation of osteopontin serum levels with disease
activity in human CD [39].
In this study, we aimed to analyze the role of OPN gene variants
on IBD disease susceptibility and phenotype. We also investigated
for potential epistasis with IBD-associated IL23R gene variants. In
total, we genotyped nine common single nucleotide polymor-
phisms (SNPs) in the OPN gene, which were previously shown to
be associated with other immune-mediated diseases [40,41,42,43].
Last, based on the important role demonstrated for IL-22 in colitis
experiments in Opn2/2 mice [39], we analyzed the effect of OPN
gene variants on IL-22 serum levels.
Methods
Ethics statement
Written, informed consent was obtained from all patients prior
to inclusion into the study. In the case of minors, the consent was
provided by the parents. This study was approved by the Ethics
committee of the Medical Faculty of Ludwig-Maximilians-
University Munich. The study protocol adhered to the ethical
principles for medical research involving human subjects of the
Helsinki Declaration (as described in detail under: http://www.
wma.net/en/30publications/10policies/b3/index.html).
Study population
Our study population comprised 2819 individuals of Caucasian
origin including n=841 patients with CD, n=473 patients with
UC and n=1505 healthy unrelated controls. All phenotypic data
were collected blind to the results of genotyping and included
detailed demographic and clinical parameters (disease behaviour,
anatomic manifestation of IBD, complications, surgical or
immunosuppressive therapy). The diagnosis of CD and UC was
based on established guidelines according to endoscopic, radio-
logical, and histopathological parameters. For classification of CD
patients, the Montreal classification [44] based on age at diagnosis
(A), location (L), and behaviour (B) of disease was used. In patients
with UC, anatomic location was also based on the Montreal
classification, based on the criteria ulcerative proctitis (E1), left-
sided UC (distal UC; E2), and extensive UC (pancolitis; E3).
Patients with indeterminate colitis were excluded from the study.
The clinical characteristics of the IBD study population are shown
in Table 1.
DNA extraction
From all study participants, blood samples were taken and
genomic DNA was isolated from peripheral blood leukocytes using
the DNA blood mini kit from Qiagen (Hilden, Germany)
according to the manufacturer’s guidelines.
Genotyping of OPN gene variants
Nine OPN SNPs (rs2728127, rs2853744, rs11730582,
rs11739060, rs28357094, rs4754=p.Asp80Asp, rs1126616=
p.Ala236Ala, rs1126772 and rs9138) were genotyped by PCR
and melting curve analysis using a pair of fluorescence resonance
energy transfer (FRET) probes in a LightCyclerH 480 Instrument
(Roche Diagnostics, Mannheim, Germany) as previously described
in detail [45,46,47,48]. The selection of these SNPs was based on
previous studies in which associations for several of these OPN
variants with autoimmune and Th1- and Th17-mediated diseases
Table 1. Demographic characteristics of the IBD study
population.
Crohn’s
disease
Ulcerative
colitis Controls
n=841 n=473 n=1505
Gender
Male (%) 49.2 47.3 62.6
Female (%) 50.8 52.7 37.4
Age (yrs)
Mean 6 SD 39.4613.1 41.7614.4 45.9610.7
Range 10–80 7–85 18–71
Body mass index
Mean 6 SD 23.164.2 23.964.1
Range 13–40 15–41
Age at diagnosis
(yrs)
Mean 6 SD 27.9611.7 31.9613.4
Range 7–71 9–81
Disease duration
(yrs)
Mean 6 SD 12.268.4 11.067.7
Range 0–44 1–40
Positive family
history of IBD (%) 16.1 16.0
doi:10.1371/journal.pone.0029309.t001
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fluorescent molecule (fluorescein) at the 39-end of the sensor
probe (or the anchor probe in the case of rs2853744 and
rs11730582) is excited at its specific fluorescence excitation
wavelength (533 nm) and the energy is transferred to the acceptor
fluorescent molecule at the 59-end (LightCycler Red 610, 640 or
670) of the anchor probe (or the sensor probe in the case of
rs2853744 and rs11730582). The specific fluorescence signal
emitted by the acceptor molecule is detected by the optical unit of
the LightCycler. The sensor probe is exactly matching to one allele
of each SNP, preferentially to the rarer allele, whereas in the case
of the other allele, there is a mismatch resulting in a lower melting
temperature. The total volume of the PCR was 5 ml containing
25 ng of genomic DNA, 16Light Cycler 480 Genotyping Master
(Roche Diagnostics), 2.5 pmol of each primer and 0.75 pmol of
each FRET probe (TIB MOLBIOL, Berlin, Germany). In the case
of rs11739060, the concentration of the forward primer, and in the
case of rs1126772, the concentration of the reverse primer was
reduced to 0.5 pmol. The PCR comprised an initial denaturation
step (95uC for 10 min) and 45 cycles (95uC for 10 sec, primer
annealing temperature as given in the Supplementary data (Table
S1) for 10 sec, 72uC for 15 sec). The melting curve analysis
comprised an initial denaturation step (95uC for 1 min), a step
rapidly lowering the temperature to 40uC and holding for 2 min,
and a heating step slowly (1 acquisition/uC) increasing the
temperature up to 95uC and continuously measuring the
fluorescence intensity. The results of the melting curve analysis
have been confirmed by analyzing two patient samples for each
possible genotype using sequence analysis. For sequencing, the
total volume of the PCR was 100 ml containing 250 ng of genomic
DNA, 16PCR buffer (Qiagen, Hilden, Germany), a final MgCl2
concentration of 2 mM, 0.5 mM of a dNTP mix (Sigma,
Steinheim, Germany), 2.5 units of HotStar Plus Taq
TM DNA
polymerase (Qiagen) and 10 pmol of each primer (TIB MOL-
BIOL). The PCR comprised an initial denaturation step (95uC for
5 min), 35 cycles (denaturation at 94uC for 30 sec, primer
annealing at 60uC for 30 sec, extension at 72uC for 30 sec) and
a final extension step (72uC for 10 min). The PCR products were
purified using the QIAquick PCR Purification Kit (Qiagen) and
sequenced by a commercial sequencing company (Sequiserve,
Vaterstetten, Germany). All sequences of primers and FRET
probes and primer annealing temperatures used for genotyping
and for sequence analysis are given in Tables S1 and S2.
Genotyping of IL23R gene variants
Genotypes of 10 IBD-associated IL23R gene variants
(rs1004819, rs7517847, rs10489629, rs2201841, rs11465804,
rs11209026=p.Arg381Gln, rs1343151, rs10889677, rs11209032,
rs1495965) were available for all study patients and controls from
previous studies [4,54].
Analysis of IL-22 serum levels in CD patients
In order to investigate a potential correlation between IL-22
serum expression and OPN/SPP1 genotype, IL-22 serum levels
were determined in a subcohort of CD patients, in which serum
samples and genomic DNA was available. IL-22 serum levels for
the majority of these patients were available from a previous study
[55]. For the ELISA analysis, the human IL-22 Quantikine Elisa
Kit (R&D Systems, Minneapolis, MN) was used following the
manufacturer’s guidelines. The following steps were performed:
First, all reagents, working standards, and samples were prepared
as outlined in the manufacturer’s guidelines. Next, 100 mL of assay
diluent RD1-88 were added to each well. After this step, 100 mLo f
standard, control, or sample were added per well and incubated
for two hours at room temperature. Then, each well was aspirated
and washed four times. 200 mL of a mouse monoclonal antibody
against IL-22 conjugated to horseradish peroxidase were added
and the plates were incubated for two hours at room temperature.
After this, wells were aspirated and washed four times. Next,
200 mL of substrate solution were added to each well. The plates
were incubated for 30 minutes at room temperature to allow
colour development while being protected from light. Next, 50 mL
of stop solution were added to each well and the optical density of
each well was determined within 30 minutes, using a microplate
reader set to 450 nm. IL-22 serum levels (pg/ml) were calculated
from a standard curve of known IL-22 concentrations.
Statistical analyses
Each genetic marker was tested for Hardy-Weinberg equilib-
rium in the control population. Single-marker allelic tests were
performed with Fisher’s exact test. All tests were two-tailed,
considering p-values,0.05 as significant. Odds ratios were
calculated for the minor allele at each SNP. For multiple
comparisons, Bonferroni correction was applied where indicated.
rs4754 deviated from the Hardy-Weinberg equilibrium in the
control population (p=0.0005) and was therefore excluded from
the haplotype analysis. Haplotype analysis was conducted with
PLINK (http://pngu.mgh.harvard.edu/,purcell/plink/) and the
–hap-logistic option using a sliding-window approach with 2 up to
8 included SNPs. Interaction between different polymorphisms
were also tested with PLINK and the –epistasis command. For
analyzing potential differences of IL-22 serum levels between the
carriers of the different OPN gene variants, the mean IL-22 serum
level of carriers of the wildtype allele of each SNP was compared
with the mean IL-22 serum level of carriers of the minor allele
(=combined group of heterozygous and homozygous carriers)
using Student’s t-test.
Results
Frequency distribution of OPN gene variants and their
role in IBD susceptibility
For all three subgroups (CD, UC, and controls), the minor allele
frequencies of the nine OPN SNPs (rs2728127, rs2853744,
rs11730582, rs11739060, rs28357094, rs4754=p.Asp80Asp,
rs1126616=p.Ala236Ala, rs1126772 and rs9138) are summarized
in Table 2. With the exception of rs4754, no significant differences
in the allele frequencies were observed comparing CD and UC
patients to healthy controls (Table 2). Our analysis revealed a weak
association of SNP rs4754 (p.Asp80Asp) with CD susceptibility
(p=1.28610
22; OR (95% CI) 0.85 [0.74–0.96]). Similar to CD,
rs4754 (p.Asp80Asp) decreased susceptibility to UC, although this
association did not reach significance in univariate analysis
(p=5.25610
22; OR (95% CI) 0.85 [0.70–1.00]) (Table 2).
Moreover, both associations of rs4754 (regarding CD and UC
susceptibility) were not statistically significant after Bonferroni
correction, suggesting that these OPN variants are not major
contributors to IBD susceptibility on their own. In addition,
rs4754 deviated from the Hardy-Weinberg equilibrium in the
control population (p=0.0005) and was therefore excluded from
the haplotype analysis. However, several OPN haplotypes
were associated with CD susceptibility. As shown in table 3,
the strongest association was found for a haplotype consisting of
the 8 OPN SNPs rs2728127-rs2853744-rs11730582-rs11439060-
rs28357094-rs112661-rs1126772-rs9138 with an omnibus p-value
of 2.07610
28 (Table 3); if rs4754 would be included into this
haplotype block, the omnibus p-value would increase further to
OPN Variants in IBD Susceptibility
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212. In contrast, there were no associations of certain
OPN haplotypes with UC susceptibility (Table 4).
Analysis for gender-specific differences in OPN variants
Previous studies demonstrated significant gender-specific effects
of OPN variants in systemic lupus erythematosus (SLE) and type 1-
diabetes, particularly in male patients [43,50]. Considering the
deviation of rs4754 from the Hardy-Weinberg equilibrium, we
therefore investigated potential gender-specific effects in IBD
susceptibility. For four OPN SNPs (rs4754, rs1126616, rs1126772
and rs9138), we observed significantly different distributions
between male and female CD patients. Interestingly, for these
SNPs, there was an opposite direction of the association results for
males and females (rs4754: p=0.0004, OR=0.69 [95% CI: 0.56–
0.85] (males), p=0.7693, OR=1.03 (females); rs1126616:
p=0.1187, OR=0.85 (males), p=0.2676, OR=1.12 (females);
rs1126772: p=0.1679, OR=0.85 (males), p=0.0893, OR=1.21
(females); rs9138: p=0.1256, OR=0.85 (males), p=0.0864,
OR=1.19 (females)). Given that the most pronounced difference
between male and female CD patients was found for rs4754,
which deviated from the Hardy-Weinberg equilibrium in the
control population, we next investigated if the deviation from
Hardy-Weinberg equilibrium is based on a gender-specific effect.
This analysis revealed that there was significant deviation from
Hardy-Weinberg equilibrium in male controls (n=917;
p=0.0018), but not in female controls (n=547; p=0.1347),
confirming the gender-specific effect of this OPN SNP found in CD
patients.
Analysis for epistasis between OPN variants and IL23R
variants
To investigate if OPN variants modify IBD susceptibility by
epistastic interaction with other Th17-related IBD susceptibility
genes, we next analyzed for potential epistasis of OPN variants with
main IBD-associated IL23R variants. We found evidence of weak
epistasis between the OPN SNP rs28357094 with the IL23R SNP
rs10489629 (p=4.18610
22) and between OPN SNP rs1126616
and IL23R SNP rs2201841 (p=4.18610
22) but none of these
associations remained significant after Bonferroni correction
(Table 5).
Correlation between OPN variants and IL-22 serum levels
in CD patients
Based on the recent data of Heilmann et al. [39] demonstrating
decreased blood levels of IL-22 in acute colitis in Opn2/2 mice,
we next investigated a potential association of OPN variants and
IL-22 serum levels in a subcohort of CD patients. No correlation
was found between OPN SNPs and IL-22 serum levels (Table 6).
However, overall the IL-22 serum levels tended to be lower in the
carriers of OPN minor alleles, which was statistically significant
when the mean IL-22 expression level of carriers of the 9
investigated OPN SNPs minor alleles (homo- and heterozygous
carriers) were compared to the homozygous carriers of the
wildtype allele (p=3.6610
25). Interestingly, for 7 out of 8 OPN
SNPs forming the haplotype rs2728127-rs2853744-rs11730582-
rs11439060-rs28357094-rs112661-rs1126772-rs9138, which was
strongly associated with CD susceptibility (omnibus p-value
2.07610
28), the IL-22 serum levels were nominally lower in CD
carriers of the minor allele than in wildtype carriers, although
these differences were for each SNP only small and statistically not
significant (Table 6).
Discussion
The presented study represents the first detailed analysis of OPN
gene variants in IBD patients. In this study, there were no
significant associations of single OPN SNPs with CD or UC
susceptibility after Bonferroni correction for multiple testing;
however, several OPN haplotypes were associated with CD
susceptibility. The strongest association was found for a haplotype
consisting of the 8 OPN SNPs (rs2728127-rs2853744-rs11730582-
rs11439060-rs28357094-rs112661-rs1126772-rs9138; omnibus p-
value 2.07610
28). However, considering the strength of the
association signals found for a number of other recently identified
IBD susceptibility genes [56,57], this argues against a major role
for OPN in the genetic susceptibility for IBD. Given the strong
association of osteopontin with Th1- and Th17-mediated diseases,
the finding of an association of OPN haplotypes with CD, a Th1-
and Th17-mediated disease, but not UC susceptibility is not
surprising. In contrast, UC has been associated with a predom-
inantly modified Th2 response but partially also with a Th17
immune response. The results of our haplotype analysis suggest
Table 2. Associations of OPN/SPP1 gene markers in CD and UC case-control association studies.
Cohort Crohn’s disease Ulcerative colitis Controls
Number of individuals n=841 n=473 n=1505
Gene marker Minor allele MAF p value OR [95% CI] MAF p value OR [95% CI] MAF
rs2728127 G 0.295 0.841 0.98 [0.86–1.12] 0.274 0.162 0.89 [0.75–1.05] 0.298
rs2853744 T 0.071 0.520 0.92 [0.73–1.16] 0.080 0.725 1.05 [0.80–1.38] 0.076
rs11730582 C 0.503 0.125 1.09 [0.97–1.24] 0.495 0.430 1.06 [0.92–1.23] 0.479
rs11739060 insG 0.290 0.815 0.98 [0.86–1.12] 0.274 0.266 0.91 [0.77–1.07] 0.294
rs28357094 G 0.223 0.437 1.06 [0.92–1.23] 0.198 0.358 0.91 [0.76–1.10] 0.213
rs4754=p.Asp80Asp C 0.281 0.013 0.85 [0.74–0.96] 0.282 0.053 0.85 [0.70–1.00] 0.316
rs1126616=p.Ala236Ala T 0.279 0.892 0.99 [087–1.13] 0.285 0.804 0.97 [0.82–1.14] 0.281
rs1126772 G 0.220 0.852 1.01 [0.87–1.17] 0.213 0.783 0.97 [0.81–1.17] 0.218
rs9138 C 0.278 0.919 1.01 [0.88–1.15] 0.280 0.868 1.02 [0.86–1.20] 0.276
Minor allele frequencies (MAF), allelic test P-values, and odds ratios (OR, shown for the minor allele) with 95% confidence intervals (CI) are depicted for both the CD and
UC case-control cohorts. rs4754 deviated from the Hardy-Weinberg equilibrium (HWE) in the control population (p=0.0005) and was therefore excluded from further
analysis.
doi:10.1371/journal.pone.0029309.t002
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risk of CD. This is in agreement with recent results of the
International IBD Genetics Consortium which identified a total of
71 CD susceptibility loci [56]. These 71 susceptibility loci explain
only slightly more than 20% of CD heritability. Therefore, it is
assumed that a number of rare SNPs and haplotypes contribute to
the overall CD risk such as recently shown by us for PXR gene
variants [58]. In addition, most likely a high number of common
CD risk genes with small effect size are still unidentified but for
their identification very large cohorts would be required.
So far, genetic variants in the OPN gene have shown to be
involved in susceptibility to other immune-mediated diseases such
as SLE [59,60], oligoarticular juvenile idiopathic arthritis [61] and
sarcoidosis [51]. Despite promising functional data, previous
genotype analyses could not confirm OPN as significant disease-
modifying gene in classical Th17-mediated diseases such as
multiple sclerosis [62,63] and rheumatoid arthritis [64]. Investi-
gating the role of OPN as a susceptibility gene in SLE, a recent
study demonstrated a significant association in male patients [50] –
a phenomenon also seen in a study investigating OPN variants in
type-1 diabetes, implicating a potential gender-specific mechanism
acting in the autoimmune process [43]. Similarly, our analysis
demonstrated gender-specific effects for four OPN SNPs, partic-
ularly for rs4754 which deviated from the Hardy-Weinberg
equilibrium in male controls. Moreover, there was a significant
association of this SNP with CD in male but not in female patients.
While osteopontin is closely involved in the Th1- and Th17-
mediated immune response associated with CD [31,32,33,34], its
role in murine colitis models is controversially discussed. In one
study, osteopontin deficiency protected mice from DSS-induced
colitis [38], while in another study, osteopontin administration in
Opn2/2 mice reduced the disease activity index, improved red
blood cell counts, and reduced gut neutrophil activity compared
with the DSS-treated wildtype mice [37]. Interestingly, a recent
study demonstrated that Opn
2/2 mice showed decreased blood
levels of IL-22 [39]. Since we recently demonstrated that IL-22
serum levels are increased in CD and correlate with disease
activity and the IL23R genotype [55], we next analyzed a potential
association between OPN genotypes and IL-22 serum levels in CD
patients. Overall, we observed lower IL-22 serum levels in the
carriers of OPN minor alleles (homo- and heterozygous carriers),
which was statistically significant when the mean IL-22 expression
level of carriers of the 9 investigated OPN SNPs minor alleles was
compared to the mean IL-22 serum level of the carriers of the
Table 3. Haplotypes of OPN SNPs in Crohn’s disease (CD) case-control sample (846 cases and 1510 controls) and omnibus p-values
for association with CD susceptibility.
Haplotype combination Omnibus p-value
rs2728127-rs2853744 9.09610
21
rs2853744-rs11730582 2.74610
21
rs11730582-rs11439060 6.87610
22
rs11439060-rs28357094 2.25610
21
rs28357094-rs1126616 6.11610
21
rs1126616-rs1126772 1.81610
21
rs1126772-rs9138 4.71610
21
rs2728127-rs2853744-rs11730582 1.95610
21
rs2853744-rs11730582-rs11439060 1.34610
21
rs11730582-rs11439060-rs28357094 5.37610
22
rs11439060-rs28357094-rs1126616 2.72610
21
rs28357094-rs1126616-rs1126772 3.72610
21
rs1126616-rs1126772-rs9138 6.45610
21
rs2728127-rs2853744-rs11730582-rs11439060 2.15610
22
rs2853744-rs11730582-rs11439060-rs28357094 1.62610
21
rs11730582-rs11439060-rs28357094-rs1126616 1.35610
21
rs11439060-rs28357094-rs1126616-rs1126772 2.74610
21
rs28357094-rs1126616-rs1126772-rs9138 6.77610
21
rs2728127-rs2853744-rs11730582-rs11439060-rs28357094 3.77610
22
rs2853744-rs11730582-rs11439060-rs28357094-rs1126616 1.98610
21
rs11730582-rs11439060-rs28357094-rs1126616-rs1126772 6.95610
22
rs11439060-rs28357094-rs1126616-rs1126772-rs9138 3.84610
21
rs2728127-rs2853744-rs11730582-rs11439060-rs28357094-rs112661 5.03610
22
rs2853744-rs11730582-rs11439060-rs28357094-rs1126616-rs1126772 6.86610
22
rs11730582-rs11439060-rs28357094-rs1126616-rs1126772-rs9138 5.75610
22
rs2728127-rs2853744-rs11730582-rs11439060-rs28357094-rs112661-rs1126772 1.44610
27
rs2853744-rs11730582-rs11439060-rs28357094-rs1126616-rs1126772-rs9138 2.76610
25
rs2728127-rs2853744-rs11730582-rs11439060-rs28357094-rs112661-rs1126772-rs9138 2.07610
28
Significant p-values,0.05 are depicted in bold. All significant p-values remained significant after 10.000 permutations.
doi:10.1371/journal.pone.0029309.t003
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values for association with UC susceptibility.
Haplotype combination Omnibus p-value
rs2728127-rs2853744 5.62610
21
rs2853744-rs11730582 3.72610
21
rs11730582-rs11439060 7.01610
21
rs11439060-rs28357094 9.54610
21
rs28357094-rs1126616 8.08610
21
rs1126616-rs1126772 2.80610
21
rs1126772-rs9138 2.65610
21
rs2728127-rs2853744-rs11730582 5.24610
21
rs2853744-rs11730582-rs11439060 6.86610
21
rs11730582-rs11439060-rs28357094 8.62610
21
rs11439060-rs28357094-rs1126616 7.28610
21
rs28357094-rs1126616-rs1126772 3.86610
21
rs1126616-rs1126772-rs9138 3.02610
21
rs2728127-rs2853744-rs11730582-rs11439060 8.26610
21
rs2853744-rs11730582-rs11439060-rs28357094 4.98610
21
rs11730582-rs11439060-rs28357094-rs1126616 8.39610
21
rs11439060-rs28357094-rs1126616-rs1126772 1.97610
21
rs28357094-rs1126616-rs1126772-rs9138 5.24610
21
rs2728127-rs2853744-rs11730582-rs11439060-rs28357094 5.02610
21
rs2853744-rs11730582-rs11439060-rs28357094-rs1126616 8.25610
21
rs11730582-rs11439060-rs28357094-rs1126616-rs1126772 5.07610
21
rs11439060-rs28357094-rs1126616-rs1126772-rs9138 3.01610
21
rs2728127-rs2853744-rs11730582-rs11439060-rs28357094-rs112661 7.27610
21
rs2853744-rs11730582-rs11439060-rs28357094-rs1126616-rs1126772 5.85610
21
rs11730582-rs11439060-rs28357094-rs1126616-rs1126772-rs9138 5.36610
21
rs2728127-rs2853744-rs11730582-rs11439060-rs28357094-rs112661-rs1126772 5.86610
21
rs2853744-rs11730582-rs11439060-rs28357094-rs1126616-rs1126772-rs9138 5.95610
21
rs2728127-rs2853744-rs11730582-rs11439060-rs28357094-rs112661-rs1126772-rs9138 5.00610
21
None of the haplotypes was significantly associated with UC susceptibility (p.0.05).
doi:10.1371/journal.pone.0029309.t004
Table 5. Analysis for epistatic interactions between OPN SNPs and IL23R SNPs regarding CD susceptibility (based on 1510 controls
and 704 cases).
OPN SNPs rs2728127 rs2853744 rs11730582 rs11439060 rs28357094 rs1126616 rs1126772 rs9138
IL23R SNPs
rs1004819 5.45610
21 1.34610
21 3.00610
21 8.83610
21 5.93610
21 3.69610
21 2.86610
21 4.52610
21
rs7517847 4.52610
21 7.94610
21 2.53610
21 5.96610
21 3.98610
21 8.57610
21 4.97610
21 5.79610
21
rs10489629 1.90610
21 3.31610
21 5.54610
21 2.32610
21 4.18610
22 8.05610
21 4.31610
21 6.28610
21
rs2201841 2.49610
21 2.18610
21 2.43610
21 1.74610
21 5.91610
22 4.71610
22 6.46610
22 8.10610
22
rs11465804 8.02610
21 5.97610
21 5.98610
21 7.45610
21 9.86610
22 6.19610
21 4.54610
21 6.18610
21
rs11209026= 6.71610
21 8.056610
21 2.466610
21 6.64610
21 5.17610
21 8.87610
21 6.29610
21 9.76610
21
p.Arg381Gln
rs1343151 6.65610
21 2.25610
21 9.68610
21 7.34610
21 1.23610
21 9.98610
21 3.32610
21 8.79610
21
rs10889677 2.49610
21 3.09610
21 3.29610
21 1.53610
21 6.05610
22 5.88610
22 8.51610
22 9.73610
22
rs11209032 4.46610
21 2.92610
21 2.71610
21 3.58610
21 2.71610
21 1.91610
21 3.46610
21 3.75610
21
rs1495965 1.79610
21 2.77610
21 9.52610
22 1.34610
21 1.11610
21 1.94610
21 2.82610
21 2.39610
21
Significant p-values,0.05 are depicted in bold. However, these associations did not remain significant after Bonferroni correction.
doi:10.1371/journal.pone.0029309.t005
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25). In 7 out of 8 OPN/
SPP1 SNPs forming the haplotype rs2728127-rs2853744-
rs11730582-rs11439060-rs28357094-rs112661-rs1126772-rs9138,
which was strongly associated with CD susceptibility, the IL-22
serum levels were nominally lower in CD carriers of the minor
allele than in homozygous wildtype carriers, although these
differences were for each SNP only small and statistically not
significant. Similarly, there were no significant associations with
CD or UC susceptibility with single OPN SNPs after Bonferroni
correction, suggesting that only the combined effect of certain OPN
SNPs and haplotypes leads to decreased basal IL-22 levels and
increased CD susceptibility. We therefore hypothesize that certain
OPN variants may increase the CD risk via decreased basal
expression of IL-22, for which we and others demonstrated strong
epithelial-protective properties [65,66,67,68]. However, given the
multitude of functions mediated by osteopontin, other disease-
modulating properties of OPN haplotypes are likely and need
further functional investigation.
In addition to increased wound healing, IL-22 mediates also
early host defense against attaching and effacing bacterial
pathogens [69,70]. In line with the data of Heilmann et al. [39]
demonstrating a dual role of osteopontin in intestinal inflamma-
tion, one might therefore hypothesize that carriers of OPN minor
alleles with lower IL-22 serum levels are at high risk of developing
intestinal inflammation due to the lack of IL-22-induced mucosal
protection. Interestingly, Opn2/2 mice demonstrated altered
wound healing [71], which may be also related to decreased
expression of IL-22, which is a strong enhancer of intestinal wound
healing [65].
Recent studies in mice showed that osteopontin is involved in
Th17 cell differentiation [72] and Opn-expressing DCs induce IL-
17 production in T cells [21]. On the other hand, osteopontin
expression in DCs is repressed by IFN-a and IFN-c [73,74]. This
decreased osteopontin expression is associated with high produc-
tion of IL-27, a Th17 cell-inhibiting cytokine that favors regulatory
T cell development [75]. We recently demonstrated that IL-27 is
also a protective factor for the intestinal epithelial barrier [76]. IL-
27 induces anti-inflammatory and antibacterial responses in
intestinal epithelial cells and increases cell restitution after
wounding [76]. In mice with Opn-deficient DCs, substantially
elevated levels of IL-27 are produced and Opn
2/2 mice develop
delayed experimental autoimmune encephalitis with a Th1 rather
than Th17-dominated response [73]. Opn
2/2 mice display a
stronger Th1-mediated proinflammatory response during chronic
inflammation while a reduced Th17 response during acute colitis
protects them from mucosal inflammation [39], further strength-
ening the dual role of osteopontin in intestinal inflammation.
In summary, our study identified certain OPN haplotypes to be
associated with CD susceptibility. OPN variants may modulate
IL-22 secretion which is consistent with data in Opn2/2 mice, in
which low levels of the epithelial-protective cytokine IL-22
predispose to intestinal inflammation. However, the rather weak
association signals found in this study argue against a significant
role for OPN as major IBD susceptibility gene which is consistent
with the recent IBD meta-analyses [56,57]. Further functional
analysis of large cohorts and detailed fine mapping is required to
clarify the role of OPN variants in the genetic susceptibility to
IBD.
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Table 6. OPN gene variants modulate IL-22 serum levels in CD patients.
OPN SNP IL-22 serum levels IL-22 serum levels p-value
in OPN wildtype in OPN minor allele
carriers [pg/ml] carriers* [pg/ml]
rs2728127 39.72 37.28 0.537
rs2853744 38.24 39.54 0.854
rs11730582 42.07 37.18 0.341
rs11439060 39.72 37.28 0.537
rs28357094 39.23 37.36 0.614
rs4754=p.Asp80Asp 40.19 36.78 0.380
rs1126616=p.Ala236Ala 40.19 36.59 0.357
rs1126772 41.04 34.96 0.106
rs9138 40.35 36.59 0.333
Mean 40.08 37.06 3.66610
25
The mean IL-22 serum level was analyzed for each OPN variant in a subgroup of 151 CD patients for which DNA for genotyping and serum for ELISA analysis was
available. P values are given for the comparison of the mean IL-22 serum levels of carriers of the minor allele (*homozygous and heterozygous) compared to cytokine
levels in homozygous wild-type carriers.
doi:10.1371/journal.pone.0029309.t006
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